Yulia Glick Gorman

Yulia Glick Gorman

Auto-generated profile, based on publicly available information

Yulia Glick Gorman

Oncology Institute, Sheba Medical Center, Tel Hashomer, Israel

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2023 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
CSChani Stossel
Chani Stossel
MRMaria Raitses-Gurevich
Maria Raitses-Gurevich
DADikla Atias
Dikla Atias
TBTamar Beller
Tamar Beller
YGYulia Glick Gorman
Yulia Glick Gorman
TGTalia Golan
Talia Golan
Germline BRCA–associated pancreatic ductal adenocarcinoma (glBRCA PDAC) tumors are susceptible to platinum and PARP inhibition. The clinical outcomes of 125 patients with glBRCA PDAC were stratified based on the spectrum of response to platinum/PARP inhibition: (i) refractory [overall survival (OS) <6 months], (ii) durable response followed by acquired resistance (OS 36 months). Patient-derived xenografts (PDX) were generated from 25 patients with glBRCA PDAC at different clinical time points. Response to platinum/PARP inhibition in vivo and ex vivo culture (EVOC) correlated with clinical response. We deciphered the mechanisms of resistance in glBRCA PDAC and identified homologous recombination (HR) proficiency and secondary mutations restoring partial functionality as the most dominant resistant mechanism. Yet, a subset of HR-deficient (HRD) patients demonstrated clinical resistance. Their tumors displayed basal-like molecular subtype and were more aneuploid. Tumor mutational burden was high in HRD PDAC and significantly higher in tumors with secondary mutations. Anti–PD-1 attenuated tumor growth in a novel humanized glBRCA PDAC PDX model. This work demonstrates the utility of preclinical models, including EVOC, to predict the response of glBRCA PDAC to treatment, which has the potential to inform time-sensitive medical decisions. Significance: glBRCA PDAC has a favorable response to platinum/PARP inhibition. However, most patients develop resistance. Additional treatment options for this unique subpopulation are needed. We generated model systems in PDXs and an ex vivo system (EVOC) that faithfully recapitulate these specific clinical scenarios as a platform to investigate the mechanisms of resistance for further drug development. This article is highlighted in the In This Issue feature, p. 1749


14 July 2023
Verified
Other
Open access
PDF file
CSChani Stossel
Chani Stossel
MRMaria Raitses-Gurevich
Maria Raitses-Gurevich
DADikla Atias
Dikla Atias
TBTamar Beller
Tamar Beller
YGYulia Glick Gorman
Yulia Glick Gorman
TGTalia Golan
Talia Golan
In vivo growth kinetics and EVOC efficacy in acquired resistance model



14 July 2023
Verified
Other
Open access
PDF file
CSChani Stossel
Chani Stossel
MRMaria Raitses-Gurevich
Maria Raitses-Gurevich
DADikla Atias
Dikla Atias
TBTamar Beller
Tamar Beller
YGYulia Glick Gorman
Yulia Glick Gorman
TGTalia Golan
Talia Golan
In vivo growth kinetics and EVOC efficacy in acquired resistance model